Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

NCT06222437 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2026-03-23

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Semaglutide

effectiveness of semaglutide in PCOS

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-28
Primary Completion
2026-02-28
Completion
2027-02-28
FDA Drug
Yes

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06222437 on ClinicalTrials.gov